<DOC>
	<DOCNO>NCT00352677</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness INNO-406 adult patient imatinib-resistant intolerant Philadelphia chromosome-positive ( Ph+ ) leukemia .</brief_summary>
	<brief_title>Safety Tolerability Study INNO-406 Treat Chronic Myeloid Leukemia Acute Lymphocytic Leukemia</brief_title>
	<detailed_description>The purpose study determine safety , tolerability pharmacokinetic profile INNO-406 administer daily oral agent adult patient imatinib-resistant intolerant Philadelphia chromosome-positive ( Ph+ ) leukemia .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<criteria>1 . Have confirm diagnosis Ph+ ALL CML chronic , accelerate , blastic phase either resistant intolerant imatinib therapy . 2 . Be ≥18 year old . 3 . Have Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤2 . 4 . Have estimate life expectancy ≥12 week . 5 . Be male nonpregnant , nonlactating female . Patients fertile must agree use effective barrier method contraception therapy 90 day follow discontinuation study drug . 6 . Have negative serum urine pregnancy test within 7 day prior first dose study drug ( patient female childbearing potential ) . 7 . Have acceptable pretreatment clinical laboratory result . 1 . Have receive chemotherapy ≤1 week start therapy , exception hydroxyurea corticosteroid . 2 . Have receive imatinib ≤3 day prior enrollment recovered side effect imatinib therapy . 3 . Have impair cardiac function . 4 . Have active , uncontrolled systemic infection consider opportunistic , lifethreatening , clinically significant time treatment . 5 . Have clinically significant acute chronic liver renal disease consider unrelated tumor . 6 . Have impair gastrointestinal function may significantly alter drug absorption ( e.g. , uncontrolled vomiting , ulcerative colitis , malabsorption , small bowel resection ) . 7 . Are pregnant lactating . 8 . Have psychiatric disorder ( ) would interfere consent , study participation , followup . 9 . Have recover acute toxicity previous therapy prior enrollment . 10 . Have severe concurrent disease and/or uncontrolled medical condition , , judgment investigator , could predispose patient unacceptable safety risk compromise compliance protocol . 11 . Have history another primary malignancy currently clinically significant require active intervention .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>